BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 27095936)

  • 1. Reduced BCL2 and CCND1 mRNA expression in human cervical cancer HeLa cells treated with a combination of everolimus and paclitaxel.
    Yilmaz A; Alp E; Onen HI; Menevse S
    Contemp Oncol (Pozn); 2016; 20(1):28-32. PubMed ID: 27095936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy Eve and Pac to induce apoptosis in cervical cancer cells by targeting PI3K/AKT/mTOR pathways.
    Dong P; Hao F; Dai S; Tian L
    J Recept Signal Transduct Res; 2018 Feb; 38(1):83-88. PubMed ID: 29369007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of EF-24, RAD001, and paclitaxel on the expression profiles of apoptotic and anti-apoptotic genes.
    Alp E; Yilmaz A; Onen HI; Menevse ES
    J Cancer Res Ther; 2017; 13(2):346-350. PubMed ID: 28643758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic activity of sunitinib and everolimus in Caki-1 renal cancer cells is accompanied by modulations in the expression of apoptosis-related microRNA clusters and BCL2 family genes.
    Papadopoulos EI; Yousef GM; Scorilas A
    Biomed Pharmacother; 2015 Mar; 70():33-40. PubMed ID: 25776476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel.
    Faried LS; Faried A; Kanuma T; Nakazato T; Tamura T; Kuwano H; Minegishi T
    Eur J Cancer; 2006 May; 42(7):934-47. PubMed ID: 16540312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mechanism and inhibitory effect of recombinant human P53 adenovirus injection combined with paclitaxel on human cervical cancer cell HeLa.
    Liu YG; Zheng XL; Liu FM
    Eur Rev Med Pharmacol Sci; 2015; 19(6):1037-42. PubMed ID: 25855930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).
    Huober J; Fasching PA; Hanusch C; Rezai M; Eidtmann H; Kittel K; Hilfrich J; Schwedler K; Blohmer JU; Tesch H; Gerber B; Höß C; Kümmel S; Mau C; Jackisch C; Khandan F; Costa SD; Krabisch P; Loibl S; Nekljudova V; Untch M; Minckwitz Gv
    Eur J Cancer; 2013 Jul; 49(10):2284-93. PubMed ID: 23541564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms.
    Kojima K; Fujita Y; Nozawa Y; Deguchi T; Ito M
    Prostate; 2010 Oct; 70(14):1501-12. PubMed ID: 20687223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines.
    Aissat N; Le Tourneau C; Ghoul A; Serova M; Bieche I; Lokiec F; Raymond E; Faivre S
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):305-13. PubMed ID: 17912526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation.
    Ota H; Eto M; Ako J; Ogawa S; Iijima K; Akishita M; Ouchi Y
    J Am Coll Cardiol; 2009 Jun; 53(24):2298-305. PubMed ID: 19520256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
    Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
    Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of GRP78 in the Resistance of Ovarian Carcinoma Cells to Paclitaxel.
    Zhang LY; Li PL; Xu A; Zhang XC
    Asian Pac J Cancer Prev; 2015; 16(8):3517-22. PubMed ID: 25921171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of survivin enhances paclitaxel-induced Hela cell apoptosis.
    Gu F; Li L; Yuan QF; Li C; Li ZH
    Eur Rev Med Pharmacol Sci; 2017 Aug; 21(15):3504-3509. PubMed ID: 28829489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-21 inhibitor suppresses cell proliferation and colony formation through regulating the PTEN/AKT pathway and improves paclitaxel sensitivity in cervical cancer cells.
    Du G; Cao D; Meng L
    Mol Med Rep; 2017 May; 15(5):2713-2719. PubMed ID: 28447761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonistic anticancer effect of paclitaxel and digoxin combination.
    Pereira DG; Rendeiro MM; Cortes VF; Barbosa LA; Quintas LEM
    J Cell Biochem; 2019 Aug; 120(8):13107-13114. PubMed ID: 30883884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of BCL2 (ala43thr), CCND1 (G870A) and FAS (A-670G) polymorphisms in modulating the risk of developing esophageal cancer.
    Jain M; Kumar S; Lal P; Tiwari A; Ghoshal UC; Mittal B
    Cancer Detect Prev; 2007; 31(3):225-32. PubMed ID: 17561354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The epigenetically regulated effects of Wnt antagonists on the expression of genes in the apoptosis pathway in human bladder cancer cell line (T24).
    Varol N; Konac E; Onen IH; Gurocak S; Alp E; Yilmaz A; Menevse S; Sozen S
    DNA Cell Biol; 2014 Jul; 33(7):408-17. PubMed ID: 24665856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination effects of paclitaxel with signaling inhibitors in endometrial cancer cells.
    Xu C; Li X; Li T; Wang X; Yang Y; Xiao L; Shen H
    Asian Pac J Cancer Prev; 2011; 12(11):2951-7. PubMed ID: 22393970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The tumorigenic role of DSPP and its potential regulation of the unfolded protein response and ER stress in oral cancer cells.
    Gkouveris I; Nikitakis NG; Aseervatham J; Ogbureke KUE
    Int J Oncol; 2018 Oct; 53(4):1743-1751. PubMed ID: 30015841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.